search

Active clinical trials for "Coronary Stenosis"

Results 91-100 of 273

The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers

Diabetes MellitusCoronary Artery Stenosis

People with diabetes mellitus are more prone to coronary heart disease, stroke, and peripheral vascular disease, and diabetes mellitus has been regarded as an independent risk factor for the progression of coronary artery disease. Several studies have been reported that diabetes increased the risk of cardiovascular mortality in both men and women. With the introduction of drug-eluting stents (DESs), the angiographic rates of restenosis at later months have reduced dramatically in several studies. However, even with DESs, diabetic patients showed increased rates of restenosis and late loss index compared with nondiabetic patients. Diabetes has been considered to be a predictor of poor prognosis after percutaneous coronary intervention with drug-eluting stents. Long-term clinical and angiographic outcomes after percutaneous coronary intervention (PCI) with drug-metal stents (DESs) have been demonstrated to be worse in diabetic patients compared with nondiabetic patients. In the era of DESs, no study has demonstrated the clinical and angiographic outcomes in diabetic patients after zotarolimus-eluting stent implantation by using intravascular ultrasound (IVUS). Pioglitazone is used in the treatment of diabetic patients. Thiazolidinediones increase insulin sensitivity and show favorable effect on blood glucose levels and lipid profiles. The effect of pioglitazone on neointima volume and inflammatory markers has not been compared in prospective manner after zotarolimus-eluting stent implantation. The purpose of this prospective, randomized, single blinded trial is to compare the effect of pioglitazone on inflammatory markers and neointima volume by using IVUS in diabetic patients.

Completed18 enrollment criteria

SPIRIT PRIME Clinical Trial

Myocardial IschemiaCoronary Artery Stenosis3 more

To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.

Completed55 enrollment criteria

Excel Drug-Eluting Stent Pilot Clinical Registry

Coronary Stenosis

The Trial aims to evaluate long-term efficiency of Excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.

Completed9 enrollment criteria

Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent

Coronary Stenosis

The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events.

Completed11 enrollment criteria

Shockwave Coronary Lithoplasty Study

Coronary Stenosis

The objective of this clinical trial is to study the early safety and feasibility of the Shockwave Coronary Lithoplasty System. To demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, de novo coronary lesions.

Completed38 enrollment criteria

Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty

Stable AnginaCoronary Stenosis

We aimed to evaluate feasibility and the 6-month angiographic and OCT results of FFR - guided use of paclitaxel-eluting balloons (Sequent Please™, B Braun) with provisional bare metal stenting for elective PCI of de novo coronary lesions.

Completed13 enrollment criteria

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

Chronic Total Occlusion of Coronary ArteryVascular Disease5 more

XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

Completed14 enrollment criteria

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control...

Coronary OcclusionThrombosis (Stent Thrombosis)6 more

This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System (SECSS) ("CYPHER SELECT PLUS") during commercial use in China.

Completed33 enrollment criteria

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente

Coronary Artery DiseaseAngina Pectoris3 more

The TWENTE Study is a single center prospective single-blinded randomized study. Randomization will involve the type of Drug-Eluting Stent (DES) used in study population. Patients will be blinded to the type of DES they will receive. The general practitioner of the patient will be requested not to disclose this information to the patient. Analysts who perform the data analyses will be blinded to the type DES used as well.

Completed11 enrollment criteria

ABSORB EXTEND Clinical Investigation

Myocardial IschemiaCoronary Artery Stenosis4 more

The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the ABSORB Bioresorbable Vascular Scaffold (BVS) System ABSORB BVS is currently in development at Abbott Vascular.

Completed12 enrollment criteria
1...91011...28

Need Help? Contact our team!


We'll reach out to this number within 24 hrs